KRBP - Kiromic BioPharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Kiromic BioPharma, Inc.

7707 Fannin Street
Suite 200
Houston, TX 77054
United States

Full-time employees31

Key executives

NameTitlePayExercisedYear born
Mr. Pietro Bersani CPA, J.D.CEO, Principal Financial Officer & Director546.76kN/A1968
Jason MorrisChief Financial OfficerN/AN/AN/A
Dr. Leonardo Mirandola Ph.D.CSO & Interim COON/AN/AN/A
Dr. Scott Dahlbeck M.D., Pharm.D., PharmDChief of StaffN/AN/A1962
Mr. Timothy Simkiss CPAControllerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Corporate governance

Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.